Literature DB >> 20839897

Flupirtine in pain management: pharmacological properties and clinical use.

Jacques Devulder1.   

Abstract

Flupirtine is a centrally acting, non-opioid analgesic that is available in a number of European countries for the treatment of a variety of pain states. The therapeutic benefits seen with flupirtine relate to its unique pharmacological properties. Flupirtine displays indirect NDMA receptor antagonism via activation of potassium channels and is the first representative of a pharmacological class denoted the 'selective neuronal potassium channel openers'. The generation of the M-current is facilitated by flupirtine via the opening of neuronal Kv7 potassium channels. The opening of these channels inhibits exaggerated neuronal action potential generation and controls neuronal excitability. Neuronal hyperexcitability is a physiological component of many pain states such as chronic pain, migraine and neurogenic pain. Although large-scale clinical trials are lacking, the clinical trial database available to date from smaller-scale studies, together with extensive clinical experience, indicate that flupirtine effectively reduces chronic musculoskeletal pain, migraine and neuralgias, amongst other types of pain. In addition, flupirtine produces, at recommended clinical doses, muscle-relaxing effects in the presence of abnormally increased muscle tension. Its analgesic and muscle-relaxant properties were comparable to tramadol and chlormezanone, respectively, in two prospective trials in patients with lower back pain. Cytoprotective, anti-apoptotic and antioxidant properties have also been associated with flupirtine use in a small number of studies to date. When provided as combination therapy with morphine, flupirtine increases the antinociceptive activity of morphine 4-fold. Flupirtine displays superior tolerability when compared with tramadol and pentazocine. The most common adverse effects associated with flupirtine use are drowsiness, dizziness, heartburn, dry mouth, fatigue and nausea. With respect to its molecular structure, mechanism of action and adverse event profile, flupirtine is a unique drug. Flupirtine is an analgesic with many potential therapeutic benefits that may prove useful in the treatment of many disease states.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20839897     DOI: 10.2165/11536230-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  44 in total

1.  Analgesic activity of flupirtine maleate: a controlled double-blind study with diclofenac sodium in orthopaedics.

Authors:  P Mastronardi; M D'Onofrio; E Scanni; M Pinto; S Frontespezi; M G Ceccarelli; F Bianchi; B Mazzarella
Journal:  J Int Med Res       Date:  1988 Sep-Oct       Impact factor: 1.671

2.  Prevention of glutathione depletion-induced apoptosis in cultured human RPE cells by flupirtine.

Authors:  J P Wood; G Pergande; N N Osborne
Journal:  Restor Neurol Neurosci       Date:  1998-06       Impact factor: 2.406

3.  Induction of apoptosis in cultured human retinal pigment epithelial cells is counteracted by flupirtine.

Authors:  N N Osborne; C Cazevieille; G Pergande; J P Wood
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-06       Impact factor: 4.799

4.  Putative site(s) and mechanism(s) of action of flupirtine, a novel analgesic compound.

Authors:  I Szelenyi; B Nickel
Journal:  Postgrad Med J       Date:  1987       Impact factor: 2.401

5.  Clinical trial of flupirtine maleate in patients with migraine.

Authors:  R Million; B R Finlay; J R Whittington
Journal:  Curr Med Res Opin       Date:  1984       Impact factor: 2.580

Review 6.  Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states.

Authors:  H A Friedel; A Fitton
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

7.  [Long-term tolerance of flupirtine. Open multicenter study over one year].

Authors:  W M Herrmann; R Hiersemenzel; M Aigner; M Lobisch; H Riethmüller-Winzen; I Michel
Journal:  Fortschr Med       Date:  1993-05-30

8.  Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.

Authors:  Muriel B Sättler; Sarah K Williams; Clemens Neusch; Markus Otto; Jens R Pehlke; Mathias Bähr; Ricarda Diem
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

9.  Efficacy and tolerance of flupirtine and pentazocine in two multicentre trials.

Authors:  J H Heusinger
Journal:  Postgrad Med J       Date:  1987       Impact factor: 2.401

10.  [Pharmacokinetics and biotransformation of the analgesic flupirtine in humans].

Authors:  P Hlavica; G Niebch
Journal:  Arzneimittelforschung       Date:  1985
View more
  27 in total

1.  Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years.

Authors:  Martin C Michel; Piotr Radziszewski; Christian Falconer; Daniela Marschall-Kehrel; Koenraad Blot
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

2.  Flupirtine is a safe alternative drug in patients with hypersensitivity to NSAIDs.

Authors:  Regina Treudler; Katja Pohle; Jan Christoph Simon
Journal:  Eur J Clin Pharmacol       Date:  2011-03-09       Impact factor: 2.953

3.  Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.

Authors:  Werner Siegmund; Christiane Modess; Eberhard Scheuch; Karen Methling; Markus Keiser; Ali Nassif; Dieter Rosskopf; Patrick J Bednarski; Jürgen Borlak; Bernd Terhaag
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

4.  Concomitant facilitation of GABAA receptors and KV7 channels by the non-opioid analgesic flupirtine.

Authors:  Felicia Klinger; Petra Geier; Mario M Dorostkar; Giri K Chandaka; Arsalan Yousuf; Isabella Salzer; Helmut Kubista; Stefan Boehm
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

5.  Flupirtine drug-induced liver injury in a patient developing acute liver failure.

Authors:  David Noiva Perdigoto; Pedro Amaro; Manuela Ferreira; Luis Tomé
Journal:  BMJ Case Rep       Date:  2018-03-09

6.  Modulation of K(v)7 potassium channels by a novel opener pyrazolo[1,5-a]pyrimidin-7(4H)-one compound QO-58.

Authors:  F Zhang; Y Mi; J L Qi; J W Li; M Si; B C Guan; X N Du; H L An; H L Zhang
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

7.  Flupirtine-induced liver injury--seven cases from the Berlin Case-control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database.

Authors:  Antonios Douros; Elisabeth Bronder; Frank Andersohn; Andreas Klimpel; Michael Thomae; Hans-Dieter Orzechowski; Reinhold Kreutz; Edeltraut Garbe
Journal:  Eur J Clin Pharmacol       Date:  2013-12-24       Impact factor: 2.953

Review 8.  Electroencephalography and analgesics.

Authors:  Lasse Paludan Malver; Anne Brokjaer; Camilla Staahl; Carina Graversen; Trine Andresen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 9.  [Non-opioid pain medication in the elderly].

Authors:  H Burkhardt; M Wehling
Journal:  Schmerz       Date:  2015-08       Impact factor: 1.107

Review 10.  Physiology and Therapeutic Potential of SK, H, and M Medium AfterHyperPolarization Ion Channels.

Authors:  Deepanjali Dwivedi; Upinder S Bhalla
Journal:  Front Mol Neurosci       Date:  2021-06-03       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.